Natco seeks to block Gilead's hepatitis C drug patent in India: source

India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.

http://in.reuters.com/article/2014/04/10/us-natco-pharma-sovaldi-idINBREA390VK20140410

YOU ARE BEING REDIRECTED TO THE ARTICLE
. . .
× CLOSE

PROCESSING